Seeking Alpha·Sep 14, 2026
NovoCure Limited (NVCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptNovoCure Limited (NVCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Novocure's LUNAR-driven NSCLC launch is gaining traction, with 2026Q2 revenue reaching a record $183.6M (up 15.6% YoY) and operating loss narrowing to -$10.6M, the smallest in the dataset. Gross margin expansion to 77.6% and a sharp deleveraging (D/E down from...
Price trend, volume and key moving averages
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Jul 23, 2026 | -$0.13+60.8% vs -$0.33 | $184M+6.5% vs $172M |
Q2 2026 Apr 30, 2026 | -$0.62-21.0% vs -$0.51 | $174M+3.7% vs $168M |
Q1 2026 Feb 26, 2026 | -$0.22+46.3% vs -$0.41 | $174M-0.0% vs $174M |
Q4 2025 Oct 30, 2025 | -$0.33+21.4% vs -$0.42 | $167M-4.1% vs $174M |
NovoCure Limited (NVCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
NVCR says a cyber incident exposed limited patient and contact data, but devices stayed secure and operations remained fully functional.
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that management will participate in two upcoming investor events. Wells Fargo 21st Annual Healthcare Conference, September 9, 2026: Frank Leonard, Chief Executive Officer, will take part in a fireside chat at 10:15 a.m. ET, as well as one-on-one meetings with investors. Morgan Stanley 24th Annual Global Healthcare Conference, September 14, 2026: Mr. Leonard and Christoph Brackmann, Chief Financial Officer, will take par.
Oncology company Novocure said on Tuesday a cybersecurity incident involving unauthorized access to certain information systems in mid-August exposed internal records of more than 1,400 U.S. patients.
Benchmark NVCR against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Novocure Ltd (NVCR)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $16.67 | $1.93B | -13.66 | 8.28% | -20.79% | -38.89% | — | |
| $60.97 | $2.02B | -6.27 | -43.89% | -287.84% | -37.99% | — | |
| $20.98 | $1.55B | 6.36 | 18.52% | 80.56% | 30.03% | — | |
| $43.75 | $2.54B | -64.34 | 8.63% | -13.23% | -10.42% | — | |
| $26.41 | $4.52B | 11.53 | 11.87% | 33.42% | 32.39% | — | |
| $521.50 | $41.14B | 39.87 | 10.42% | 25.03% | 71.96% | — |
Novocure Ltd (NVCR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Novocure Ltd (NVCR) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 23, 2026·SEC
Jun 30, 2026·SEC
Jun 18, 2026·SEC
Get notified when NVCR posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Novocure Ltd (NVCR) stock FAQ — growth, dividends, profitability & financials explained
Novocure Ltd (NVCR) reported $699.2M in revenue for fiscal year 2025. This represents a 6650% increase from $10.4M in 2013.
Novocure Ltd (NVCR) grew revenue by 8.3% over the past year. This is steady growth.
Novocure Ltd (NVCR) reported a net loss of $148.6M for fiscal year 2025.
Novocure Ltd (NVCR) has a return on equity (ROE) of -38.9%. Negative ROE indicates the company is unprofitable.
Novocure Ltd (NVCR) had negative free cash flow of $21.1M in fiscal year 2025, likely due to heavy capital investments.
